News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
All Stories
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
News
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
Press Release
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
News
Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD
July 17, 2023
BioCentury
Read Now
Press Release
Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD
July 17, 2023
BioCentury
Read Now
News
Sanofi goes back to Scribe
July 17, 2023
Evaluate
Read Now
Press Release
Sanofi goes back to Scribe
July 17, 2023
Evaluate
Read Now